Entera Bio Ltd
NASDAQ:ENTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.5507
2.98
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ENTX stock under the Base Case scenario is 0.02 USD. Compared to the current market price of 1.61 USD, Entera Bio Ltd is Overvalued by 99%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Entera Bio Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ENTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Entera Bio Ltd
Balance Sheet Decomposition
Entera Bio Ltd
Current Assets | 7.3m |
Cash & Short-Term Investments | 6.9m |
Receivables | 111k |
Other Current Assets | 314k |
Non-Current Assets | 401k |
PP&E | 381k |
Other Non-Current Assets | 20k |
Current Liabilities | 1.1m |
Accounts Payable | 184k |
Accrued Liabilities | 927k |
Non-Current Liabilities | 178k |
Other Non-Current Liabilities | 178k |
Earnings Waterfall
Entera Bio Ltd
Revenue
|
99k
USD
|
Cost of Revenue
|
-90k
USD
|
Gross Profit
|
9k
USD
|
Operating Expenses
|
-7.2m
USD
|
Operating Income
|
-7.1m
USD
|
Other Expenses
|
-12k
USD
|
Net Income
|
-7.2m
USD
|
Free Cash Flow Analysis
Entera Bio Ltd
USD | |
Free Cash Flow | USD |
ENTX Profitability Score
Profitability Due Diligence
Entera Bio Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Entera Bio Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
ENTX Solvency Score
Solvency Due Diligence
Entera Bio Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Entera Bio Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENTX Price Targets Summary
Entera Bio Ltd
According to Wall Street analysts, the average 1-year price target for ENTX is 10.2 USD with a low forecast of 10.1 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for ENTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ENTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.
Contact
IPO
Employees
Officers
The intrinsic value of one ENTX stock under the Base Case scenario is 0.02 USD.
Compared to the current market price of 1.61 USD, Entera Bio Ltd is Overvalued by 99%.